InsightRX Unveils InsightRX GEMINI(SM)

InsightRX, renowned for its expertise in Bayesian model-informed precision dosing software, has introduced InsightRX GEMINI℠. This advanced algorithm for vancomycin dosing, which leverages a vast dataset from over 384,000 patient treatments, was made available to select users on July 30, 2024.

Clinical recommendations for vancomycin dosing typically rely on the area under the plasma drug concentration-time curve (AUC). Accurate AUC estimation is heavily influenced by the chosen model and method, often making it a labor-intensive process. InsightRX GEMINI℠ streamlines this by enabling clinicians to determine appropriate dosing with a single click. The software accomplishes this by:

1. Parsing patient data relevant to vancomycin's pharmacokinetics.
2. Selecting an initial pharmacokinetic (PK) model from InsightRX's validated catalog.
3. Utilizing InsightRX's extensive real-world data network to find historical patient matches.
4. Reviewing and summarizing performance data to select the optimal PK model for dosing.

With the experience of treating over a million patients over seven years, InsightRX GEMINI℠ automates the identification of the best vancomycin PK model at the beginning of therapy. Key patient characteristics, such as body mass index (BMI) and age, are considered to minimize bias and enhance overall model performance, fostering a standardized approach across healthcare systems.

External validation of the GEMINI℠ algorithm, using a separate dataset of 144,000 patients, showed a significant increase in prediction accuracy by up to 47% compared to a single-model approach. InsightRX aimed to develop an algorithm that could adapt to a wide range of patient characteristics, resulting in a 20-50% improvement in dosing prediction accuracy over previous iterations.

The development of this innovative algorithm draws on the combined expertise of InsightRX’s data scientists and clinical pharmacists. This follows the company's recent success with the first commercially available precision dosing model for heparin.

CEO and co-founder of InsightRX, Sirj Goswami, Ph.D., highlighted the benefit GEMINI℠ offers to clinicians. By automating the model selection process, it eliminates manual patient-factor selection, thereby expediting the dosing review process at the point of care.

InsightRX plans to present more about InsightRX GEMINI℠ at the ASHP Midyear meeting in New Orleans from December 8-12. Here, they will showcase their latest products and features designed to enhance precision dosing's impact.

InsightRX is a healthcare technology company that offers a cloud-based clinical decision support platform. This platform integrates quantitative pharmacology and artificial intelligence to improve therapeutic decision-making from drug development phases to clinical care. By providing individualized predictions of patient responses to treatment, InsightRX's technology aids clinicians in optimizing medication effectiveness and understanding dose-response relationships and toxicity.